TITLE:
A Study of Viracept in HIV-Positive Women

CONDITION:
HIV Infections

INTERVENTION:
Nelfinavir mesylate

SUMMARY:

      The purpose of this study is to see if it is safe and effective to give Viracept plus
      stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400
      cells/mm3. This study also examines how the body handles Viracept when given with d4T and
      3TC.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have:

          -  HIV infection.

          -  CD4 T cell count <= 400 cells/mm3.

        Exclusion Criteria

        Prior Medication:

        Excluded:

          -  Prior therapy or less than 1 month of therapy with d4T and/or 3TC.

          -  Prior protease inhibitor therapy.
      
